TY - JOUR
T1 - Effect of granulocyte colony-stimulating factor treatment on ex vivo blood cytokine response in human volunteers
AU - Hartung, Thomas
AU - Döcke, Wolf Dietrich
AU - Gantner, Florian
AU - Krieger, Gerhard
AU - Sauer, Achim
AU - Stevens, Paul
AU - Volk, Hans Dieter
AU - Wendel, Albrecht
N1 - Copyright:
Copyright 2020 Elsevier B.V., All rights reserved.
PY - 1995/5/1
Y1 - 1995/5/1
N2 - We explored the ex vivo alterations in the cytokine release of stimulated blood taken from healthy volunteers treated subcutaneously with 480 μg granulocyte colony-stimulating factor (G-CSF). In a double-blind, controlled, randomized study with 21 volunteers who received G-CSF once or twice 24 hours apart, we measured lipopolysaccharide (LPS)-inducible release of various cytokines and soluble receptors at different times after treatment. At day I after a single dose of G-CSF, mediator release was also initiated with muramyl dipeptide, Staphylococcus aureus enterotoxin A, lipoteichoic acid, streptolysin O, complement factor C5a, phytohemagglutinin, or phorbol myristate acetate. In blood from G-CSF-treated subjects, our major findings were (1) a maximal 12-fold increase in interleukin-1 receptor antagonist (IL- 1ra) release and an increase of both the p55 and p75 soluble tumor necrosis factor (TNF) receptors; (2) a reduction in TNF release when using all the various stimuli described except LPS; (3) an increase in G-CSF and, to lesser extent, in IL-6, IL-8, and IL-10 release; and (4) an attenuation of interferon-γ (IFN-γ) and granulocyte-macrophage (GM)-CSF release. Our findings demonstrate that the major effect of G-CSF treatment is a change in the responsiveness of blood towards a variety of stimuli, which we interpret as a shift toward an antiinflammatory cytokine response.
AB - We explored the ex vivo alterations in the cytokine release of stimulated blood taken from healthy volunteers treated subcutaneously with 480 μg granulocyte colony-stimulating factor (G-CSF). In a double-blind, controlled, randomized study with 21 volunteers who received G-CSF once or twice 24 hours apart, we measured lipopolysaccharide (LPS)-inducible release of various cytokines and soluble receptors at different times after treatment. At day I after a single dose of G-CSF, mediator release was also initiated with muramyl dipeptide, Staphylococcus aureus enterotoxin A, lipoteichoic acid, streptolysin O, complement factor C5a, phytohemagglutinin, or phorbol myristate acetate. In blood from G-CSF-treated subjects, our major findings were (1) a maximal 12-fold increase in interleukin-1 receptor antagonist (IL- 1ra) release and an increase of both the p55 and p75 soluble tumor necrosis factor (TNF) receptors; (2) a reduction in TNF release when using all the various stimuli described except LPS; (3) an increase in G-CSF and, to lesser extent, in IL-6, IL-8, and IL-10 release; and (4) an attenuation of interferon-γ (IFN-γ) and granulocyte-macrophage (GM)-CSF release. Our findings demonstrate that the major effect of G-CSF treatment is a change in the responsiveness of blood towards a variety of stimuli, which we interpret as a shift toward an antiinflammatory cytokine response.
UR - http://www.scopus.com/inward/record.url?scp=0028927105&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0028927105&partnerID=8YFLogxK
U2 - 10.1182/blood.v85.9.2482.bloodjournal8592482
DO - 10.1182/blood.v85.9.2482.bloodjournal8592482
M3 - Article
C2 - 7537116
AN - SCOPUS:0028927105
SN - 0006-4971
VL - 85
SP - 2482
EP - 2489
JO - Blood
JF - Blood
IS - 9
ER -